CQDM, Feldan Therapeutics and Amgen fund development of innovative drug delivery technology to target lung diseases

CQDM is proud to announce the funding of a project worth $503,779 aiming at optimizing a new drug delivery platform in the lungs to treat several disabling pathologies such as chronic pulmonary obstruction and cystic fibrosis. CQDM is providing a grant of $201,512, made possible by the Ministère de l’Économie et de l’Innovation et de l’Énergie (MEIE). This funding, combined with the support of the Quebec company Feldan Therapeutics and the biotech company Amgen, will support the development of new therapeutic options. This project is part of a larger collaboration between the two companies, worth $1,427,757, to expand the potential of Feldan’s unique drug delivery technology.

NewsGuest UserApril 20, 2023BIOOQuébecCQDM, Feldan Therapeutics, Amgen, Drug delivery, lung diseases

nplex-McGill partnership selected by CQDM for a $1M grant to apply next-generation ELISA in drug discovery

McGill University and CQDM announced today that a collaborative project between McGill and nplex biosciences to further develop a highly-scalable protein detection method, termed the “nELISA”, has been selected for funding by CQDM.

NewsGuest UserJuly 23, 2020CQDM, biopharmaceutical, Mesentech, Technology, Drug delivery, bone

CQDM becomes a shareholder of Mesentech to support the validation of a highly promising bone-targeting drug delivery technology

The CQDM is launching its new SynergiQc program, designed to stimulate industrial research in the biopharmaceutical field within academic settings and to create economic benefits for Quebec.